EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid simultaneous detection of katG S315T and rpoB S531L mutations for molecular screening of multidrug-resistant tuberculosis using a dual LAMP-lateral flow assay

Jutturong Ckumdee, Somchai Santiwatanakul, Nakarin Vutipow, Thongchai Kaewphinit iD

Microbiology Spectrum · 03.11.2026 · 14 (11)

DOI: 10.1128/spectrum.02195-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.11.2026. Verfasst von Jutturong Ckumdee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Mycobacterium tuberculosis, Bacterial Proteins, DNA-Directed RNA Polymerases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Srinakharinwirot University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global spread of multidrug-resistant tuberculosis (MDR-TB) remains a major challenge to tuberculosis control programs, particularly in resource-limited settings where access to rapid molecular drug-susceptibility testing is limited. Resistance to isoniazid and rifampicin is most commonly associated with mutations in the katG and rpoB genes, respectively, making these loci valuable molecular markers for early MDR-TB screening. In this study, we developed a dual loop-mediated isothermal amplification assay coupled with lateral flow detection for the simultaneous identification of the katG S315T and rpoB S531L mutations in Mycobacterium tuberculosis . Mutation-specific primer sets were designed using mismatch amplification principles to achieve single-nucleotide specificity. Amplification was performed at 61°C for 60 min, followed by visual detection on a three-line lateral flow strip within 5 min. The assay demonstrated a preliminary detection threshold of approximately 10 CFU/mL equivalents and exhibited no cross-reactivity with wild-type M. tuberculosis H37Rv, non-tuberculous mycobacteria, or non-target resistance-associated mutations, including the inhA −15 promoter mutation and rpoB codon 526 variants. Preliminary clinical feasibility was evaluated using genetically characterized clinical sputum specimens and showed complete concordance with GenoType MTBDRplus and Sanger DNA sequencing results. Because the assay targets only two resistance-associated mutations, a negative result does not exclude isoniazid or rifampicin resistance mediated by alternative mutations. IMPORTANCE These proof-of-concept findings demonstrate the initial feasibility of a rapid, low-complexity molecular platform for the simultaneous detection of clinically important resistance-associated mutations in Mycobacterium tuberculosis . The assay represents a promising step toward low-complexity molecular screening for selected multidrug-resistant tuberculosis-associated mutations, bringing us closer to simplified testing in settings where access to conventional molecular drug-resistance testing remains limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantMycobacterium tuberculosisBacterial ProteinsDNA-Directed RNA PolymerasesCatalaseNucleic Acid Amplification TechniquesMolecular Diagnostic TechniquesHumansAntitubercular AgentsRifampinSensitivity and SpecificityMutationIsoniazidRapid Diagnostic TestsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Mycobacterium tuberculosisdrug-resistance mutationsloop-mediated isothermal amplification (LAMP)molecular diagnosticsmultidrug-resistant tuberculosis

Substanzen

Bacterial ProteinsDNA-Directed RNA PolymerasesrpoB protein, Mycobacterium tuberculosisCatalasekatG protein, Mycobacterium tuberculosisAntitubercular AgentsRifampinIsoniazid

Autor:innen und Institutionen

  • Department of Clinical Pathology, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
  • Department of Pathology, Faculty of Medicine, Srinakharinwirot University, Nakhonnayok, Thailand.
  • Genetic Engineering and Bioinformatics Interdisciplinary Program, Graduate School, Kasetsart University, Bangkok, Thailand.
  • Center of Excellence in Medical and Environmental Innovation Research (CEMEIR), Srinakharinwirot University, Bangkok, Thailand.
  • Innovative Learning Center, Srinakharinwirot University, Bangkok, Thailand.

ORCID-Profile: Thongchai Kaewphinit

Förderung

  • Srinakharinwirot University

Zitieren

APA

Ckumdee, J., Santiwatanakul, S., Vutipow, N., & Kaewphinit, T. (2026). Rapid simultaneous detection of katG S315T and rpoB S531L mutations for molecular screening of multidrug-resistant tuberculosis using a dual LAMP-lateral flow assay. Microbiology Spectrum, 14(11). https://doi.org/10.1128/spectrum.02195-26

Vancouver

Ckumdee J, Santiwatanakul S, Vutipow N, Kaewphinit T. Rapid simultaneous detection of katG S315T and rpoB S531L mutations for molecular screening of multidrug-resistant tuberculosis using a dual LAMP-lateral flow assay. Microbiology Spectrum. 2026;14(11). doi:10.1128/spectrum.02195-26

BibTeX
@article{Ckumdee2026,
  author = {Ckumdee, Jutturong and Santiwatanakul, Somchai and Vutipow, Nakarin and Kaewphinit, Thongchai},
  title = {Rapid simultaneous detection of katG S315T and rpoB S531L mutations for molecular screening of multidrug-resistant tuberculosis using a dual LAMP-lateral flow assay},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1128/spectrum.02195-26}
}
Kostenlos starten →